Forest Archives - Regulatory Professionals

November 28, 2012

Forest Submits Schizophrenia Drug with FDA

Forest Laboratories has filed a New Drug Application (NDA) in the USA for the antipsychotic Cariprazine. Cariprazine, which was discovered by Hungary’s Gedeon Richter and licensed to Forest in the USA and Canada, has been submitted for the treatment of both schizophrenia and manic or mixed episodes connected to bipolar I disorder.

Written by Stephen Smith

November 16, 2011

Almirall Start Phase III trials & Announce Collaboration with BioFocus

Spain’s Almirall yesterday announced that they have linked up with UK drug discovery firm BioFocus to find new hit compounds against key targets of interest to Almirall. These compounds will be used to support projects targeted at the treatment of respiratory and inflammatory conditions. BioFocus, the service division of Belgium’s Galapagos, will apply their screening

Regulatory Professionals

Regulatory Affairs Recruitment

Forest

Forest Submits Schizophrenia Drug with FDA

Almirall Start Phase III trials & Announce Collaboration with BioFocus

Like to Talk to a Consultant?